Back to Journals » Drug Design, Development and Therapy » Volume 8

Efficacy of the small molecule inhibitor of Lipid II BAS00127538 against Acinetobacter baumannii

Authors de Leeuw EPH

Received 20 May 2014

Accepted for publication 10 June 2014

Published 8 August 2014 Volume 2014:8 Pages 1061—1064

DOI https://doi.org/10.2147/DDDT.S68020

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Erik PH de Leeuw

Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA

Objective: To test the activity of a small molecule compound that targets Lipid II against Acinetobacter baumannii.
Methods: Susceptibility to small molecule Lipid II inhibitor BAS00127538 was assessed using carbapenem- and colistin-resistant clinical isolates of A. baumannii. In addition, synergy between colisitin and this compound was assessed.
Results: Small molecule Lipid II inhibitor BAS00127538 potently acts against A. baumannii and acts synergistically with colistin.
Conclusion: For the first time, a compound that targets Lipid II is described that acts against multi-drug resistant isolates of A. baumannii. The synergy with colistin warrants further lead development of BAS00127538.

Keywords: Lipid II, Acinetobacter baumannii, drug development

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Effect of a small molecule Lipid II binder on bacterial cell wall stress

Malin J, Shetty AC, Daugherty SC, de Leeuw EPH

Infection and Drug Resistance 2017, 10:69-73

Published Date: 28 February 2017

A novel small-molecule inhibitor of HIV-1 entry

Heredia A, Latinovic OS, Barbault F, de Leeuw EPH

Drug Design, Development and Therapy 2015, 9:5469-5478

Published Date: 1 October 2015

Structure–activity exploration of a small-molecule Lipid II inhibitor

Fletcher S, Yu W, Huang J, Kwasny SM, Chauhan J, Opperman TJ, MacKerell Jr AD, de Leeuw EPH

Drug Design, Development and Therapy 2015, 9:2383-2394

Published Date: 24 April 2015

Readers of this article also read:

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone

Hu Z, Liao M, Chen Y, Cai Y, Meng L, Liu Y, Lv N, Liu Z, Yuan W

International Journal of Nanomedicine 2012, 7:5719-5724

Published Date: 12 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010